1. Merck's Experimental HIV Prevention Pill Could Cost Under $5 Per Year, Analysis Shows
A new analysis reveals Merck's experimental HIV prevention pill, MK 8527, could be mass-produced for less than $5 per patient annually. This strikingly low potential cost is fueling pressure on the pharmaceutical giant to license the drug for broad access in low- and middle-income countries, where the HIV burden is hig...